Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 10/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24589117 | 0.97 | GLP1R (0.52) | GLP1RFOLH1HPGDHTTSMN1; SMN2 | |
| SCHEMBL24589118 | 0.90 | FOLH1 (0.46) | GLP1RFOLH1 | |
| SCHEMBL22223445 | 0.90 | GLP1R (0.49) | GLP1RFOLH1HPGDHTTSMN1; SMN2 | |
| SCHEMBL22223463 | 0.87 | GLP1R (0.53) | GLP1RFOLH1HPGDHTTSMN1; SMN2 | |
| SCHEMBL24588463 | 0.85 | GLP1R (0.52) | GLP1RFOLH1 | |
| SCHEMBL23083064 | 0.85 | FOLH1 (0.43) | FOLH1HPGDHTTSMN1; SMN2 | |
| SCHEMBL24589077 | 0.85 | GLP1R (0.55) | GLP1RFOLH1 | |
| SCHEMBL22134424 | 0.84 | GLP1R (0.38) | GLP1RFOLH1 | |
| SCHEMBL22134589 | 0.84 | GLP1R (0.38) | GLP1RFOLH1 | |
| SCHEMBL24589065 | 0.84 | GLP1R (0.51) | GLP1RFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | GLP1R 2800/4885FOLH1 1272/4885HPGD 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.